Study Details

Back to Search Results

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants with Overactive Bladder (OAB)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02138747

Astellas Study ID

The unique identification code given by the study sponsor.

178-MA-1001

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Overactive Bladder Disease

Phase

These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jul 2014 - Nov 2015

Masking

Double (Participant, Investigator)

Enrollment number

376

A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects with Overactive Bladder (OAB)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants with Overactive Bladder (OAB)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US10019 Chesapeake Urology Research Associates

Towson, United States, 21204

Site CA15005 CHUS - Hopital Fleurimont

Sherbrooke, Canada, J1H 5N4

Site US10016 Suffolk OB/GYN, LLP

Port Jefferson, United States, 11777

Site US10035 Millennium Clinical Research Center

Arlington, United States, 22203

Site US10005 Boston Clinical Trials

Boston, United States, 02131

Site CA15012 Glover Medical Clinic

Langley, Canada, V3A 4H9

Site US10033 Eastern Research

Hialeah, United States, 33013

Site US10022 Palm Beach Research Center

West Palm Beach, United States, 33409

Site US10009 North Shore LIJ Health System

Great Neck, United States, 11021

Site US10001 Urological Associates of Southern Arizona

Tucson, United States, 85715

Site US10002 Urology Centers of Alabama

Homewood, United States, 35209

Site US10010 Skyline Urology

Sherman Oaks, United States, 91411

Site CA15001 Jonathan Giddens Medicine Professional Corporation

Brampton, Canada, L6T 4S5

Site CA15002 RechercheGCP Research

Granby, Canada, J2G 8Z9

Site US10015 Nevada Access To Research and Education Society

Las Vegas, United States, 89106

Site CA15008 Silverado Research

Victoria, Canada, V8T 2C1

Site US10024 Coastal Connecticut Research, LLC

New London, United States, 06320

Site US10023 Advanced Clinical Research of Miami

Miami, United States, 33155

Site US10007 Pinellas Urology, Inc

Saint Petersburg, United States, 33710

Site US10057 Practice Research Organization

Dallas, United States, 75230

Site US10013 Advanced Urology Centers of New York

Plainview, United States, 11803

Site US10008 The Iowa Clinic PC, Urology

West Des Moines, United States, 50266

Site US10021 AccuMed Research Associates

Garden City, United States, 11530-1664

Site US10020 Upstate Clinical Research Associates LLC

Williamsville, United States, 14221

Site US10017 The Jackson Clinic

Jackson, United States, 38305

Site CA15011 Scisco Clinical Research

Cornwall, Canada, K6H 4M4

Site US10003 Genesis Research

San Diego, United States, 92123

Site CA15007 RechercheGCP Research

Montreal, Canada, H1M 1B1

Site US10034 Health Research of Hampton Roads Inc

Newport News, United States, 23606

Site US10028 Clinical Research Consulting

Milford, United States, 06460

Site CA15003 The Male/Female Health & Research Centre

Barrie, Canada, L4M 7G1

Site US10006 Skyline Urology

Torrance, United States, 90505

Site US10004 Alaska Clinical Research Center, LLC

Anchorage, United States, 99503

Site US10014 Mid Atlantic Clinical Research

Greenbelt, United States, 20770

Site US10018 Institute for Female Pelvic Medicine

Allentown, United States, 18103

Site US10032 Clinical Research and Consulting Center, LLC

Fairfax, United States, 22030

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo